Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by Lynx9on Aug 19, 2021 11:33am
161 Views
Post# 33730434

RE:Clear Sailing

RE:Clear SailingThere is so much going on with this company! With the interest from respected Boston affiliates and with that comes new credited board and management members so it hard to realize that PMN is still a long ways off the mark however, it's promising a very new and exciting possibility. New money, new talent and new and knowlegeable investors are starting to give PMN the credability it was so lacking. For those of us long term shareholders and when I say longterm, "mad cow comes to mind", it's time to just release the reins a bit and let the possitives take over your mind set. If you have nothing to say that adds to the brighter future of PMN then, as RC recently says, just move on !

Just to remind those of you are wanting to cash out tomorrow because you think we are home free then let me remind you this is still experimental - "ProMIS intends to use the proceeds to advance its lead Alzheimer’s therapy PMN310 to the filing of an Investigational New Drug application to enable a first clinical trial."
 
 
And for those who watch the stock price minute by minute, wait for this to approach $.63 for wts to ever be exercised. 
"subject to an acceleration provision such that in the event that following the Closing the Common Shares have a volume weighted average price on the Toronto Stock Exchange (“TSX”) greater than three (3) times the Warrant exercise price for each of ten (10) consecutive trading days"


To another 40 days in the wilderness, believe!
Lynx9
 
<< Previous
Bullboard Posts
Next >>